Artrya Limited (ASX:AYA)
Australia · Delayed Price · Currency is AUD 1.030
+0.005 (0.49%)
Jul 25, 2025, 4:10 PM AEST
Artrya Company Description
Artrya Limited, a medical technology company, engages in the development and commercialisation of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia.
The company offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography scans which identifies and manages patients at risk of a heart attack.
Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.
Artrya Limited
| Country | Australia |
| Founded | 2018 |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | John Konstantopoulos |
Contact Details
Address: 1257 Hay Street West Perth, 6005 Australia | |
| Phone | 61 8 6478 7816 |
| Website | artrya.com |
Stock Details
| Ticker Symbol | AYA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000182412 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Ted Schwab | Co-Chief Executive Officer of Artrya USA Inc |
| John Konstantopoulos B.E. | Co-Founder and Chief Executive Officer |
| Bernard William Ridgeway F.A.C.I.D. | Executive Chair |
| Harvey Farrington | Acting Chief Financial Officer |
| Prof. Girish Dwivedi M.D. | Chief Scientific Officer |
| Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary |